Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Gufic BioSciences Ltd

About the Company - Gufic BioSciences Ltd

Gufic BioSciences Ltd. is a Public Limited Listed company incorporated on 23/07/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1984PLC033519 and registration number is 033519. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 779.16 Cr. and Equity Capital is Rs. 9.69 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069info@guficbio.com
http://www.gufic.com
Management
NamePosition Held
Mr. Jayesh P ChoksiChairman & Managing Director
Mr. Pranav J ChoksiWholeTime Director & CEO
Mr. Pankaj J GandhiWhole Time Director
Mr. Dilip B GhoshWhole Time Director
Dr. Balram H SinghNon Exe.Non Ind.Director
Mr. Shreyas K PatelIndependent Director
Mr. Shrirang V VaidyaIndependent Director
Dr. Anu S AuoraIndependent Director
Dr. Rabi N SahooIndependent Director
Mr. Gopal M DaptariIndependent Director

Gufic BioSciences Ltd. Share Price Update

Share PriceValue
Today₹331.00
Previous Day₹336.55

Basic Stock Data of Gufic BioSciences Ltd

Market Cap 3,145 Cr.
Current Price 314
High / Low365/177
Stock P/E37.3
Book Value 39.0
Dividend Yield0.03 %
ROCE22.6 %
ROE25.8 %
Face Value 1.00

Data Source: screener.in

Gufic BioSciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales128167132251194172162165175177173195215
Expenses99139108205158139130132142143141160176
Operating Profit29272446363333333334323539
OPM %23%16%18%18%18%19%20%20%19%19%19%18%18%
Other Income2011020011110
Interest4431211122344
Depreciation5344445456644
Profit before tax23201742302926282727242831
Tax %25%24%25%25%23%27%23%26%26%25%24%26%25%
Net Profit17151331232120212020182123
EPS in Rs2.231.991.653.222.412.172.092.172.082.101.872.132.39

Gufic BioSciences Ltd Quarterly Chart

Gufic BioSciences Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales8198121148201245306351379488779691760
Expenses7487109134181222267305327404631556619
Operating Profit7111214202339465284148135141
OPM %9%11%10%10%10%9%13%13%14%17%19%20%19%
Other Income0011114464333
Interest34446691014145814
Depreciation222444451416192220
Profit before tax3567101430353058127107110
Tax %49%37%32%36%29%37%45%38%25%23%24%25%
Net Profit23447916222344968082
EPS in Rs0.200.430.550.540.951.172.132.822.925.689.898.228.49
Dividend Payout %25%12%9%9%5%4%2%2%2%2%1%1%

Gufic BioSciences Ltd Profit & Loss Yearly Chart

Gufic BioSciences Ltd Growth

Compounded Sales Growth
10 Years:22%
5 Years:18%
3 Years:22%
TTM:15%
Compounded Profit Growth
10 Years:37%
5 Years:39%
3 Years:52%
TTM:3%
Stock Price CAGR
10 Years:51%
5 Years:34%
3 Years:42%
1 Year:46%
Return on Equity
10 Years:30%
5 Years:31%
3 Years:32%
Last Year:26%

Gufic BioSciences Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital888888881010101010
Reserves1215181926304668120164259338381
Borrowings20353333435780981266264334359
Other Liabilities343252677584104106152157188179220
Total Liabilities7490111127152178238280408392521861969
Fixed Assets182730252222232483100115160165
CWIP130000210311341170258
Investments0000000000011
Other Assets556081102130156213245294279365531546
Total Assets7490111127152178238280408392521861969

Gufic BioSciences Ltd Reserves and Borrowings Chart

Gufic BioSciences Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 551111-4-4-554787106-27
Cash from Investing Activity -3-13-3-2-1-5-9-13-43-7-95-191
Cash from Financing Activity -28-7-557148-4-79-6234
Net Cash Flow0014-0-11-002517

Gufic BioSciences Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days10175858210278971071039371109
Inventory Days137143144165180190238190249138102202
Days Payable180144176223188132192157238162125143
Cash Conversion Cycle58745425941361431411146948167
Working Capital Days8271644876841091281108058136
ROCE %15%18%17%18%24%24%33%30%21%29%46%23%

Gufic BioSciences Ltd Financial Efficiency Indicators Chart

Gufic BioSciences Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters65.75%65.13%75.48%75.48%75.48%75.00%75.00%75.00%75.00%75.00%75.00%72.51%
FIIs0.23%0.14%1.52%1.69%1.51%1.38%0.06%0.16%0.72%0.70%0.72%0.47%
DIIs8.24%3.24%2.13%1.19%1.12%1.13%1.16%1.16%1.16%1.16%1.63%1.72%
Public25.77%31.49%20.87%21.64%21.89%22.49%23.76%23.67%23.12%23.12%22.64%25.29%
No. of Shareholders19,63943,88335,13534,58038,14440,12041,37640,56238,90238,62436,55734,424

Gufic BioSciences Ltd Shareholding Pattern Chart

No. of Gufic BioSciences Ltd Shareholders

Gufic BioSciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
SBI Healthcare Opportunities Fund10000001.3226.08
Quant Business Cycle Fund4386031.7811.44
Motilal Oswal Nifty Microcap 250 Index Fund230730.130.6
Motilal Oswal S&P BSE Healthcare ETF2470.080.01
Groww Nifty Total Market Index Fund5300

Gufic BioSciences Ltd ROCE Trend

Gufic BioSciences Ltd EPS Trend

Gufic BioSciences Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)8.229.894.562.342.82
Diluted EPS (Rs.)8.229.894.562.342.82
Cash EPS (Rs.)10.5211.656.243.773.42
Book Value[Excl.RevalReserv]/Share (Rs.)35.8827.7617.8913.349.68
Book Value[Incl.RevalReserv]/Share (Rs.)35.8827.7617.8913.349.68
Dividend / Share (Rs.)0.100.100.100.050.05
Revenue From Operations / Share (Rs.)71.2480.3750.3139.0845.07
PBDIT / Share (Rs.)14.1515.359.045.976.44
PBIT / Share (Rs.)11.8613.587.364.545.85
PBT / Share (Rs.)11.0113.085.953.114.54
Net Profit / Share (Rs.)8.229.894.562.342.82
PBDIT Margin (%)19.8619.1017.9715.2814.29
PBIT Margin (%)16.6416.9014.6211.6212.97
PBT Margin (%)15.4516.2711.837.9510.07
Net Profit Margin (%)11.5412.309.065.986.25
Return on Networth / Equity (%)22.9135.6125.5017.5429.11
Return on Capital Employeed (%)20.0639.3731.2326.2548.83
Return On Assets (%)9.2518.3811.285.567.84
Long Term Debt / Equity (X)0.540.170.200.150.15
Total Debt / Equity (X)0.890.220.290.871.27
Asset Turnover Ratio (%)0.991.711.221.101.36
Current Ratio (X)1.611.721.591.141.25
Quick Ratio (X)0.971.101.020.620.74
Inventory Turnover Ratio (X)2.273.371.971.421.35
Dividend Payout Ratio (NP) (%)1.211.010.871.711.76
Dividend Payout Ratio (CP) (%)0.950.850.641.061.45
Earning Retention Ratio (%)98.7998.9999.1398.2998.24
Cash Earning Retention Ratio (%)99.0599.1599.3698.9498.55
Interest Coverage Ratio (X)16.6930.706.434.164.94
Interest Coverage Ratio (Post Tax) (X)10.6920.774.242.633.16
Enterprise Value (Cr.)2074.202447.631146.65553.37680.30
EV / Net Operating Revenue (X)3.003.142.351.461.94
EV / EBITDA (X)15.1216.4513.089.5613.56
MarketCap / Net Operating Revenue (X)2.623.102.271.211.69
Retention Ratios (%)98.7898.9899.1298.2898.23
Price / BV (X)5.208.976.393.537.86
Price / Net Operating Revenue (X)2.623.102.271.211.69
EarningsYield0.040.030.030.040.03

Gufic BioSciences Ltd Profitability Ratios (%)

Gufic BioSciences Ltd Liquidity Ratios

Gufic BioSciences Ltd Liquidity Ratios (%)

Gufic BioSciences Ltd Interest Coverage Ratios (%)

Gufic BioSciences Ltd Valuation Ratios

Fair Value of Gufic BioSciences Ltd Stock

Fair Value: ₹375.43

The stock is undervalued by 19.56% compared to the current price ₹314

*Investments are subject to market risks

Strength and Weakness of Gufic BioSciences Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 24.83%, which is a positive sign.
  2. The company has higher reserves (115.08 cr) compared to borrowings (103.38 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (357.54 cr) and profit (41.69 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 10.19 and average Dividend Yield of 14.55%.
  2. The stock has a high average Working Capital Days of 87.17, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 93.58, which may not be favorable.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gufic BioSciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE